Evidence map›Paper›PMID 41159022›Full record

ArticleFrontiers in immunology2025

SARS-CoV-2 vaccines induce a diverse spike-specific CD4+ T cell receptor repertoire in people living with HIV with low CD4 nadirs.

Alicia Mercado, Joel Sop, Steven Amanat, Li Zhang, Natasha M Chida, Christie R Basseth, Kelly A Gebo, Annukka A R Antar, Kellie N Smith, Zhen Zeng and 1 more

Abstract read
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Alicia Mercado *Department of Medicine, Johns Hopkins Medicine, Baltimore, MD, United States.
Joel Sop *Department of Medicine, Johns Hopkins Medicine, Baltimore, MD, United States.
Steven Amanat *Bloomberg∼Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Medicine, Baltimore, MD, United States.
Li ZhangBloomberg∼Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Medicine, Baltimore, MD, United States.
Natasha M ChidaDepartment of Medicine, Johns Hopkins Medicine, Baltimore, MD, United States.
Christie R BassethDepartment of Medicine, Johns Hopkins Medicine, Baltimore, MD, United States.
Kelly A GeboDepartment of Medicine, Johns Hopkins Medicine, Baltimore, MD, United States.
Annukka A R AntarDepartment of Medicine, Johns Hopkins Medicine, Baltimore, MD, United States.
Kellie N SmithBloomberg∼Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Medicine, Baltimore, MD, United States.
Zhen Zeng *Bloomberg∼Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Medicine, Baltimore, MD, United States.
Joel N Blankson *Department of Medicine, Johns Hopkins Medicine, Baltimore, MD, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

People living with HIV with low CD4 T cell nadirs on antiretroviral therapy have suboptimal responses to immunization. We analyzed the SARS-CoV-2 spike-specific CD4+ T cell repertoire in individuals with CD4 nadirs of less than 100 cells/ul who received a primary SARS-CoV-2 mRNA vaccine series as well as the bivalent ancestral/BA.5 spike mRNA vaccine. We tested the hypothesis that antigenic imprinting would result in the preferential expansion of pre-existing cross-reactive T cells that were primed against the 4 common cold coronaviruses. We found that these individuals made robust effector and memory T cell responses to the SARS-CoV-2 spike protein that exceeded the responses to spike proteins from the common cold coronaviruses. Furthermore, in 4 individuals, the number of SARS-CoV-2 specific TCRs far exceeded the number of common cold coronavirus-specific T cell receptors. TCRs that were cross-reactive for common cold coronaviruses and SARS-CoV-2 comprised less than 10% of the total detected SARS-CoV-2 specific T cells. The diversity of the SARS-CoV-2 spike-specific repertoire in 6 study participants was comparable to that of the repertoire in vaccinated HIV healthy donors. Our data suggests people living with HIV with low CD4 nadirs can have significant functional immune reconstitution with little evidence of antigenic imprinting due to pre-existing T cell responses to common cold coronaviruses.

Indexed as

CD4-Positive T-LymphocytesCOVID-19COVID-19 VaccinesHIV InfectionsReceptors, Antigen, T-CellSARS-CoV-2Spike Glycoprotein, CoronavirusAdultCD4 Lymphocyte CountCross ReactionsFemaleHumansMaleMiddle AgedCOVID-19 VaccinesReceptors, Antigen, T-CellSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2CD4 T cellcommon cold coronavirusesHIVSARS-CoV-2T cell receptor (TCR)

Identifiers

PMID41159022
PMCPMC12554773

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.